---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-23-000027"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2023-05-17T23:59:59+00:00"
generated_at: "2026-06-14T22:23:42.584415+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Recursion appoints CMO David Mauro; completes Valence acquisition for up to ~8.1M shares

## Summary
- David Mauro appointed CMO effective June 1; brings 20+ years oncology drug development experience from Codiak, Checkmate, Prelude, Advaxis.
- Acquisition of Valence Discovery completed; consideration includes up to ~2.2M Class A shares and ~5.9M exchangeable shares.
- Recursion assumes Valence options exercisable for up to ~0.8M Class A shares; total potential dilution up to ~8.9M shares.
- Dr. Mauro will lead Recursion's five clinical programs and growing pre-clinical pipeline.

## SEC filing metadata
- accession: 0001601830-23-000027
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2023-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000027/0001601830-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000027/rxrx-20230516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-23-000027
- JSON: https://secwatch.observer/filing/0001601830-23-000027.json
- Plain text: https://secwatch.observer/filing/0001601830-23-000027.txt

## Key facts
- Executive change
  Shafique Virani changed role as Interim Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..
  - Action: will no longer hold
  - Role: Interim Chief Medical Officer
  source text: Shafique Virani, M.D., who has been serving in the role of Chief Corporate Development Officer and Interim Chief Medical Officer, will no longer hold the position of Interim Chief Medical Officer, effective June 1, 2023, but will continue serving in the role of Chief Corporate Development Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000027/0001601830-23-000027-index.htm
- Executive change
  David Mauro was appointed as Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On May 16, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) announced that it has appointed David Mauro, M.D., Ph.D., to the position of Chief Medical Officer, effective June 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000027/0001601830-23-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.